KRAS and pancreatic intraductal papillary-mucinous neoplasm: KRAS mutations and TP53 overexpression are less frequently identified in oncocytic-type IPMN than in pancreatobiliary-type IPMN (17% and 11% versus 58% and 58%, resp).